ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 100 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2016. The put-call ratio across all filers is 0.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10 | -86.5% | 10,618 | -80.1% | 0.00% | – |
| Q2 2023 | $74 | -51.0% | 53,346 | -44.2% | 0.00% | – |
| Q1 2023 | $151 | -82.6% | 95,594 | -31.4% | 0.00% | -100.0% |
| Q4 2022 | $868 | -99.7% | 139,427 | +841.9% | 0.00% | – |
| Q3 2021 | $316,000 | +0.3% | 14,802 | -0.7% | 0.00% | – |
| Q2 2021 | $315,000 | +88.6% | 14,902 | +150.2% | 0.00% | – |
| Q1 2021 | $167,000 | -37.2% | 5,956 | -41.9% | 0.00% | – |
| Q4 2020 | $266,000 | -61.1% | 10,260 | -44.2% | 0.00% | -100.0% |
| Q3 2020 | $683,000 | -31.4% | 18,384 | -5.3% | 0.00% | -50.0% |
| Q2 2020 | $995,000 | -24.9% | 19,411 | -53.8% | 0.00% | 0.0% |
| Q1 2020 | $1,325,000 | +137.5% | 42,052 | +348.7% | 0.00% | +100.0% |
| Q4 2019 | $558,000 | +158.3% | 9,373 | +58.8% | 0.00% | 0.0% |
| Q3 2019 | $216,000 | -71.2% | 5,901 | -63.4% | 0.00% | -50.0% |
| Q2 2019 | $750,000 | +47.1% | 16,141 | +27.0% | 0.00% | +100.0% |
| Q1 2019 | $510,000 | -19.6% | 12,708 | -7.8% | 0.00% | -50.0% |
| Q4 2018 | $634,000 | +291.4% | 13,785 | +276.9% | 0.00% | +100.0% |
| Q3 2018 | $162,000 | +67.0% | 3,657 | +46.4% | 0.00% | – |
| Q2 2018 | $97,000 | +15.5% | 2,498 | +115.0% | 0.00% | -100.0% |
| Q1 2018 | $84,000 | -57.4% | 1,162 | -70.5% | 0.00% | -50.0% |
| Q3 2017 | $197,000 | +4825.0% | 3,943 | +3843.0% | 0.01% | – |
| Q2 2017 | $4,000 | -99.6% | 100 | -99.6% | 0.00% | -100.0% |
| Q1 2017 | $958,000 | +435.2% | 27,155 | +89.2% | 0.04% | +272.7% |
| Q4 2016 | $179,000 | -20.4% | 14,353 | -12.0% | 0.01% | -26.7% |
| Q3 2016 | $225,000 | +389.1% | 16,315 | +243.8% | 0.02% | +400.0% |
| Q2 2016 | $46,000 | -9.8% | 4,745 | +55.7% | 0.00% | -25.0% |
| Q1 2016 | $51,000 | -79.9% | 3,048 | -73.3% | 0.00% | -80.0% |
| Q4 2015 | $254,000 | -65.6% | 11,412 | +26.2% | 0.02% | -67.7% |
| Q2 2015 | $739,000 | +7.7% | 9,041 | +22.0% | 0.06% | -22.5% |
| Q1 2015 | $686,000 | – | 7,410 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
| Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
| Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
| BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
| Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
| PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
| Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
| Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
| Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
| SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |